CTOs on the Move

Black Diamond Therapeutics

www.blackdiamondtherapeutics.com

 
Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Using its mutation, allostery, and pharmacology (MAP) computational and discovery platform, Black Diamond is uncovering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant`s Ridgeline Discovery ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Black Diamond Therapeutics raised $20M on 12/12/2018
Black Diamond Therapeutics raised $85M on 01/09/2019

Similar Companies

VDDI Pharmaceuticals

VDDI Pharmaceuticals is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CareLink Community Support Services

CareLink Community Services provides a progressive approach to rehabilitation, wellness, & autonomy for people with disabilities.

RxHub

RxHub LLC is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Family Service Association of Bucks County

Family Service offers a variety of programs and services focused on increasing opportunities for adults, protecting seniors, reducing substance abuse, improving the lives of those with mental illness, preparing children and adolescents for the future, ...

BrainStorm Cell

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.